Immunorock Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $1.49M

  • Investors
  • 9

Immunorock General Information

Description

Developer of a biopharmaceutical platform designed to accelerate the clinical translation of academic discoveries into immunotherapies. The company's platform offers an oral cancer vaccine using genetically engineered bifidobacteria that deliver full-length tumor antigens to the gut immune system, enabling cancer patients access to a novel, non-invasive immunotherapy that induces strong cytotoxic T cell responses.

Contact Information

Website
immunorock.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2nd Floor, Research Building C, Kobe University School of Medicine
  • 7-5-1 Kusunoki-cho, Chuo-ku
  • Kobe, Kyoto 650-0017
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2nd Floor, Research Building C, Kobe University School of Medicine
  • 7-5-1 Kusunoki-cho, Chuo-ku
  • Kobe, Kyoto 650-0017
  • Japan
+81

Immunorock Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunorock Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 03-Feb-2026 $1.49M Completed Clinical Trials - Phase 1
6. Seed Round 18-Apr-2024 Completed Clinical Trials - Phase 1
5. Accelerator/Incubator 21-Sep-2023 Completed Clinical Trials - Phase 1
4. Seed Round 14-Jul-2023 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 01-Jan-2023 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator $35.2K Completed Clinical Trials - Phase 1
1. Angel (individual) $35.2K $35.2K Completed Clinical Trials - Phase 1
To view Immunorock’s complete valuation and funding history, request access »

Immunorock Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A-1
A Shares 10 $3191.79 $3191.79 1x $3191.79 6.45%
To view Immunorock’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Immunorock Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Immunorock Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026121971-A Predicting the effectiveness of cancer vaccines Active 14-Jan-2025
JP-7835418-B1 Predicting the effectiveness of cancer vaccines Active 14-Jan-2025
WO-2026155116-A1 Prediction of effects of cancer vaccine Pending 14-Jan-2025

Immunorock Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunorock Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
KNC Laboratories Corporation Minority
Kobe Shinkin Bank Corporation Minority
Kobe University Capital Venture Capital Minority
J-Startup Accelerator/Incubator
Kobe University University Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Immunorock FAQs

  • When was Immunorock founded?

    Immunorock was founded in 2021.

  • Where is Immunorock headquartered?

    Immunorock is headquartered in Kobe, Japan.

  • What is the size of Immunorock?

    Immunorock has 3 total employees.

  • What industry is Immunorock in?

    Immunorock’s primary industry is Drug Discovery.

  • Is Immunorock a private or public company?

    Immunorock is a Private company.

  • What is the current valuation of Immunorock?

    The current valuation of Immunorock is .

  • What is Immunorock’s current revenue?

    The current revenue for Immunorock is .

  • How much funding has Immunorock raised over time?

    Immunorock has raised $2.56M.

  • Who are Immunorock’s investors?

    KNC Laboratories, Kobe Shinkin Bank, Kobe University Capital, J-Startup, and Kobe University are 5 of 9 investors who have invested in Immunorock.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process